

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[← Back](#)

[Center for Cell Engineering](#)

[Main Publications & Treatment](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)


[Leadership](#)


[History](#)

[Equality, diversity & inclusion](#)


[Annual report](#)


[Give to MSK](#)





Reprinted from The Journal of Clinical Investigation, August 2016, Volume 126, Number 8.





Reprinted from Cell Stem Cell Volume 16, Issue 2, February 2015. Copyright Elsevier (2015).

A fluorescence microscopy image showing a dense population of cells. The cells are stained with two different fluorescent dyes, one emitting green light and the other red light. The green-stained cells are more numerous and form a network, while the red-stained cells are more scattered and appear as bright spots. The overall image has a dark background with vibrant green and red colors.

Science Translational Medicine

11 December 2013



< >
[Boulad F, Maggio A, Wang X, Moi P, Acuto S, Kogel F, Takpradit C, Prockop S, Mansilla-Soto J, Cabriolu A, Odak A, Qu J, Thummar K, Du F, Shen L, Raso S, Barone R, Di Maggio R, Pitrolo L, Giambona A, Mingoia M, Everett JK, Hokama P, Roche AM, Cantu VA, Adhikari H, Reddy S, Bouhassira E, Mohandas N, Bushman FD, Rivière I and Sadelain M. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with \$\beta\$ -thalassemia: a phase 1 trial. *Nature Medicine*. January 3, 2022.](#)

[Amor, C., Feucht, J., Leibold, J. et al. Senolytic CAR T cells reverse senescence-associated pathologies. *Nature*. 2020 Jul;583\(7814\):127-132.](#)

Commentary: [Crunkhorn S. Driving CARs to clear senescent cells. *Nat Rev Drug Discov*. 2020 Aug;19\(8\):509.](#)

Commentary: [Wagner V, Gil J. T cells engineered to target senescence. *Nature*. 2020 Jul;583\(7814\):37-38.](#)

[Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. *J Clin Invest*. 2019 Feb 25;129\(4\):1551-1565.](#)

Commentary: [Dhodapkar MV. Navigating the Fas lane to improved cellular therapy for cancer. *J Clin Invest*. 2019 Feb 25;129\(4\):1522-1523. doi: 10.1172/JCI127581. eCollection 2019 Feb 25.](#)

[Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerretter T, Andreas M, Sadelain M, Einsele H, Hudecek M. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. *Sci. Transl. Med*. 11, eaau5907 \(2019\).](#)

[Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, Li Z, Cunanan KM, Huse M, Hendrickson RC, Wang X, Rivière I, Sadelain M. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. *Nature*. 2019 Mar 27.](#)

[Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. *Sci Transl Med*. 2019 Mar 27;11\(485\).](#)

[Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. *Nat Med*. 2019 Mar;25\(3\):530.](#)

[Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. *Cancer Cell*. 2019 Mar 18;35\(3\):473-488.e6.](#)

[June CH, Sadelain M. Chimeric Antigen Receptor Therapy. *N Engl J Med*. 2018 Jul 5;379\(1\):64-73.](#)

Commentary: [Caulley L, Ramaswami R, Longo DL, Phimister EG, Ingelfinger JR, Ropper AH, Stern K, Burke AE, Knoper KM, Seals JJJ, Müller DC, Drazen JM. A Look Forward - The Frontiers in Medicine Series. N Engl J Med. 2018 Jul 5;379\(1\):85-86.](#)

[Dunbar C.E., High, K.A., Joung, J.K., Kohn, D.B., Ozawa, K., Sadelain M. Gene therapy comes of age. Science. 2018 Jan 12;359\(6372\).](#)

[Giavridis T., van der Stegen S.J.C., Eyquem J., Hamieh M., Piersigilli A., Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature Medicine. Online 28 May 2018. DOI: 10.1038/s41591-018-0041-7.](#)

Commentary: [Rooney C., Sauer T. Modeling cytokine release syndrome. Nature Medicine. Online 28 May 2018.](#)

[Smith M, Zakrzewski J, James S, and Sadelain M. Post-transplant chimeric antigen receptor therapy. Blood. 2018 Mar 8;131\(10\):1045-1052.](#)

[Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1;378\(5\):449-459.](#)

[Sadelain M, Rivière I. CAR T cells in cancer therapy. Nature 2017.](#)

[Sadelain M. CD19 CAR T Cells. Cell. 2017 Dec 14;171\(7\):1471.](#)

[Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 545, 423–431.](#)

[Eyquem J*, Mansilla-Soto J*, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, Odak A, Gönen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017 Mar 2;543\(7643\):113-117.](#)

*These authors contributed equally to this work.

Commentary: [Killock, D. Start your engineering — CARs take to the TRAC. Nature Reviews Clinical Oncology. Nat Rev Clin Oncol. 2017 Mar 20;14\(4\):198.](#)

[Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, Young LF, Takvorian K, Dudakov JA, Jenq RR, Hanash AM, Motta AC, Murphy GF, Liu C, Schietinger A, Sadelain M, van den Brink MR. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017 Feb;23\(2\):242-249.](#)

[Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan WC, Malek SN, Ennishi D, Brentjens RJ, Gascoyne RD, Cogné M, Tarte K, Wendel HG. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell. 2016 Oct 6;167\(2\):405-418.e13.](#)

[Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with](#)

[cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016 Aug 1;126\(8\):3130-44.](#)

Commentary: Couzin-Frankel, J. Second chapter. Science 02 Sep 2016: Vol. 353, Issue 6303, pp. 983-985.

[Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J and Sadelain M. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell. 2015 Oct 12;28\(4\):415-28.](#)

[van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015 Jul;14\(7\):499-509.](#)

[Themeli M, Rivière I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell. 2015 Apr 2;16\(4\):357-66.](#)

[Piao J, Major T, Auyeung G, Policarpio E, Menon J, Droms L, Gutin P, Uryu K, Tchieu J, Soulet D, Tabar V. Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitors Remyelinate the Brain and Rescue Behavioral Deficits following Radiation. Cell Stem Cell. 2015 Feb 5;16\(2\):198-210.](#)

[Steinbeck JA, Choi SJ, Mrejeru A, Ganat Y, Deisseroth K, Sulzer D, Mosharov EV, Studer L. Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model. Nat Biotechnol. 2015 Feb;33\(2\):204-9.](#)

[Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 5;6\(261\):261ra151.](#)

[Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science. 2014 Dec 19;346 \(6216\):1529-33.](#)

[Oricchio E, Papapetrou EP, Lafaille F, Ganat YM, Kriks S, Ortega-Molina A, Mark WH, Teruya-Feldstein J, Huse JT, Reuter V, Sadelain M, Studer L, Wendel HG. A cell engineering strategy to enhance the safety of stem cell therapies. Cell Rep. 2014 Sep 25;8\(6\):1677-85.](#)

[Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SC, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He W, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DCG, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralto S, Sadelain M, Brentjens R. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med 19 February 2014. Vol. 6, Issue 224, p. 224ra25.](#)

[Couzin-Frankel, J. Breakthrough of the Year: Cancer Immunotherapy. Science. 2013 Dec 20;342\(6165\):1432-3.](#)

[Humphries, C. Adoptive cell therapy: Honing that killer instinct. Nature. 2013 Dec 19;504\(7480\):S13-5.](#)

[Fedorov V, Themeli M, Sadelain, M. PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors \(iCARs\) Divert Off-Target Immunotherapy Responses. Sci Transl Med 11 December 2013. : Vol. 5, Issue 215, p. 215ra172.](#)

[Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013 Aug 11.](#)

Featured as "Paper of the Month" by The Latest Science

[Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblatt T, Maslak P, Frattini M and Sadelain M. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med. 2013 Mar 20;5\(177\):177ra38.](#)

Commentary: Ledford H. Engineered immune cells battle acute leukaemia. Nature. 20 March 2013.

[June C, Rosenberg SA, Sadelain M, Weber JS. T-cell therapy at the threshold. Nat Biotechnol. 2012 Jul 10;30\(7\):611-4.](#)

[Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2012 Dec 16;31\(1\):71-5.](#)

Commentary: Hanada k., Restifo N. Double or nothing on cancer immunotherapy. Nat Biotechnol. 2013 Jan;31(1):33-4.

[Dudakov JA, Hanash AM, Jenq RR, Young LF, Ghosh A, Singer NV, West ML, Smith OM, Holland AM, Tsai JJ, Boyd RL, van den Brink MR. Interleukin-22 drives endogenous thymic regeneration in mice. Science. 2012 Apr 6;336\(6077\):91-5.](#)

[Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011 Nov 6;480\(7378\):547-51.](#)

[Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M. Genomic safe harbors permit high \$\beta\$ -globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol. 2011 Jan;29\(1\):73-8.](#)

[Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118\(18\):4817-28.](#)

Commentary: Ledford, H. Cell therapy fights leukemia. Nature. 10 August 2011.

Commentary: Jacobson CA, Ritz J. Time to put the CAR-T before the horse. Blood. 2011 Nov 3;118(18):4761-2.

[Kim H, Lee G, Ganat Y, Papapetrou EP, Lipchina I, Socci ND, Sadelain M, Studer L. miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell. 2011 Jun 3;8\(6\):695-706.](#)

[Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, Tabar V, Sadelain M, Studer L. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009 Sep 17;461\(7262\):402-6.](#)

Commentary: Casci, T. Human Disease: iPSCs take the next step. Nat. Rev. Gen. 2009; 10: 662-663.

[Tabar V, Tomishima M, Panagiotakos G, Wakayama S, Menon J, Chan B, Mizutani E, Al-Shamy G, Ohta H, Wakayama T, Studer L. Therapeutic cloning in individual parkinsonian mice. Nat Med. 2008; 14\(4\): 379-81.](#)

[Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007; 13\(12\), 1440-9.](#)

[Commentary: Pardoll DM. Building the bionic T cell. Nat Med. 2007; 13\(12\), 1411-3.](#)

[Barberi T, Bradbury M, Dincer Z, Panagiotakos G, Socci ND, Studer L. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med. 2007; 13\(5\):642-8.](#)

[Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Smith OM, Grubin J, Patel N, Chow A, Cabrera-Perez J, Radhakrishnan R, Diab A, Perales MA, Rizzuto G, Menet E, Pamer EG, Heller G, Zúñiga-Pflücker JC, Alpdogan O, van den Brink MR. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med. 2006; 12\(9\):1039-47.](#)

[Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Rivière I, Sadelain M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003 Mar;9\(3\):279-86.](#)

PREVIOUS

[Support Facilities](#)

NEXT

[Special Events](#)

▼ Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▼ About MSK

[About us](#)

[Careers](#) 

[Giving](#) 

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center